Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity Meeting Abstract
| Authors: | Kris, M.; Ranson, M.; Ferry, D.; Hammond, L.; Averbuch, S.; Ochs, J.; Rowinsky, E. |
| Abstract Title: | Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity |
| Meeting Title: | 1999 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Development, and Clinical Validation |
| Journal Title: | Clinical Cancer Research |
| Volume: | 5 |
| Issue: | 11 Suppl. |
| Meeting Dates: | 1999 Nov 16-19 |
| Meeting Location: | Washington, DC |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 1999-11-01 |
| Start Page: | 3749s |
| End Page: | 3750s |
| Language: | English |
| ACCESSION: | WOS:000083945700100 |
| PROVIDER: | wos |
| PUBMED: | 10590781 |
| Notes: | Meeting Abstract: 99 -- Source: Wos |
